The efficacy and safety of mirogabalin for tha chemotherapy induced peripheral neuropathy patients in Gemcitabine+nab-Paclitaxel therapy

The efficacy and safety of mirogabalin for tha chemotherapy induced peripheral neuropathy patients in Gemcitabine+nab-Paclitaxel therapy - The efficacy and safety of mirogabalin for tha CIPN patients in GnP therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038742

Enrollment

Registered

2019-12-01

Start date

2019-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced peripheraly neuropathy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 over 20 years old 2 The patients who were treated by GnP therapy. 3 The patients who had CIPN and taken mirogabalin at least 2 weeks. 4 Informed consent had been obtained.

Exclusion criteria

Exclusion criteria: 1 The patients who could not write questionnaire. 2 The patients who were ineligible.

Design outcomes

Primary

Measure	Time frame
Patient-Reported Outcome CTCAE	—

Secondary

Measure	Time frame
EORTC-CIPN20,NRS	—

Countries

Japan

Contacts

Public ContactYusuke Takasaki

Juntendo university Department of Gastroenterology

ytakasa@juntendo.ac.jp03-3813-3111

Outcome results